Tiger Brokers

BUZZ-Eli Lilly rises on report of Medicare, Medicaid coverage for weight-loss drugs

Reuters
Aug 01, 2025
BUZZ-Eli Lilly rises on report of Medicare, Medicaid coverage for weight-loss drugs

** Shares of drugmaker Eli Lilly LLY.N rise 2% to $755 premarket

** The Trump administration is planning to cover weight-loss drugs under Medicare and Medicaid, the Washington Post reports

** The proposed plan would permit state Medicaid programs and Medicare Part D insurance plans to voluntarily cover GLP-1 drugs such as Novo Nordisk's NOVOb.CO Ozempic and Wegovy, as well as Lilly's Mounjaro and Zepbound for weight management, the report said

** The proposed plan is expected to start in April 2026 for Medicaid and January 2027 for Medicare plans, WaPo reports citing documents

** The Centers for Medicare & Medicaid Services, Eli Lilly and Novo Nordisk did not immediately respond to Reuters requests for comment

** Up to last close, LLY down 4.1% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10